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Introduction: Recently, the nuclear factor (erythroid derived 2)-like
2 (NFE2L2) gene mutations were identified in lung cancer. The
constitutive activation of NFE2L2 in lung cancer cells promotes
tumorigenicity. However, the correlation between NFE2L2mutation
status and clinicopathologic features of lung cancer has not been
well characterized.
Methods: We have investigated NFE2L2 gene mutation status in
263 surgically treated lung cancer cases at Nagoya City University
Hospital. The NFE2L2 mutation was analyzed by direct sequencing
of cDNA.
Results: We detected 13 cases (5.1%) of NFE2L2 mutation in our
cohort; all were male and all had a squamous histology. EGFR
mutations were present in 78 patients (30.8%). The NFE2L2 muta-
tion was exclusive with EGFR mutations. The NFE2L2 mutation
tended to be more frequently found in patients with advanced stages.
The patients with NFE2L2 mutation (n  13, 8 were dead) had
significantly worse prognosis than the patient with wild type
NFE2L2 (n  250, 72 were dead) (Log-rank test, p  0.0032,
Breslow-Gehan-Wilcoxon test, p  0.0028).
Conclusion: NFE2L2 mutations might play a role in tumor prog-
nosis of squamous cell carcinoma of the lung.
Key Words: NFE2L2, Squamous cell carcinoma, EGFR, Tumor
progression, mutation.
(J Thorac Oncol. 2010;5: 786–789)
Lung cancer is a major cause of death from malignantdiseases, due to its high incidence, malignant behavior and
lack of major advancements in treatment strategy.1 Lung
cancer was the leading indication for respiratory surgery
(42.2%) in 1998 in Japan.2 More than 15,000 patients under-
went surgical operation at Japanese institutions in 1998.2
The nuclear factor (erythroid derived 2)- like 2
(NFE2L2) is a master transcriptional activator of genes en-
coding many cytoprotective enzymes that are induced in
response to environmental and endogenously derived oxida-
tive/electrophilic agents.3–5 In normal cells, NFE2L2 is a cap
‘n’ collar basic leucine zipper transcription factor. NFE2L2-
deficient mice are highly susceptible to chemically induced
carcinogenesis of multiple organs.6,7 A previous report
showed that RNAi-mediated silencing of NFE2L2 gene ex-
pression in non-small cell lung cancer inhibited tumor
growth.8 NFE2L2 gene promoter polymorphism has been
identified and was suggested to be correlated with carcino-
genesis.9 More recently, NFE2L2 mutation was identified in
lung cancer tissue and cell lines.10 Somatic mutations oc-
curred in the coding region of NFE2L2 mutations were found
frequently among patients with a history of smoking or
suffering from squamous cell carcinoma and correlated with
poor prognosis.10
We investigated NFE2L2 mutation status an N-terminal
domain by direct sequencing in Japanese lung cancer. The
findings were analyzed in reference to the clinicopathologic
features of the lung cancer.
PATIENTS AND METHODS
Patients
The study group included 263 patients with lung cancer
who had undergone surgery at the Department of Surgery II,
Nagoya City University Medical School between 1997 and
2006. The lung tumors were classified according to the
general rule for clinical and pathologic record of lung cancer
in Japan. All tumor samples were immediately frozen and
stored at 80°C until assayed.
The clinical and pathologic characteristics of the 263
patients with lung cancer were as follows: 150 cases (57.0%)
at stage I, 46 at stage II (17.5%), 63 (24.0%) at stage IIII, and
four at stage IV. The mean age was 64.8 years (range,
38–83). Among the 263 patients with lung cancer, 190
(72.2%) were male and 73 (27.8%) were nonsmokers. The
samples from these patients had been already sequenced for
EGFR before.11–14
PCR Assays for NFE2L2
Total RNA was extracted from lung cancer tissues
using Isogen kit (Nippon gene, Tokyo, Japan) according to
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the manufacturers’ instructions. RNA concentration was de-
termined by spectrophotometer and adjusted to a concentra-
tion of 200 ng/ml. About 10 cases were excluded for each
assay because tumor cells were too few to sufficiently extract
tumor RNA. RNA (1 g) was reverse transcribed by Super-
script II enzyme (Gibco BRL, Gaithersburg, MD) with 0.5 g
oligo (dT)12–16 (Amersham Pharmacia Biotech Inc., Piscat-
away, NJ). The reaction mixture was incubated at 42°C for 50
minutes and then at 72°C for 15 minutes. We then used 1 L
of each DNA for polymerase chain reaction (PCR) analyses.
The PCR reactions were performed using LA-Taq kit (Takara
Bio Inc, Shiga, Japan) in a 50-L reaction volume. The
primer sequences for NFE2L2 gene were as follows: the
forward primer, 5-TCATGATGGACTTGGAGCTG-3 and
the reverse primer, 5-CTACAAACGGGAATGTCTGC-3.
The cycling conditions were as follows: initial denaturation at
94°C for 5 minutes, followed by 40 cycles at 94°C for 45
seconds, 60°C for 45 seconds, 72°C for 30 seconds. The
products were purified by Qiagen PCR purification kit (Qia-
gen, Valencia, CA). Amplified DNAs were separated on 1%
agarose gels, and the bands were visualized by ethidium
bromide and photographed under ultraviolet transillumina-
tion. These samples were sequenced by ABI prism 3100
analyzer (Applied Biosystems Japan Ltd., Tokyo, Japan) and
analyzed by BLAST and chromatograms by manual review.
Statistical Analysis
Statistical analyses were done using the Mann-Whitney
U test for unpaired samples and Wilcoxon’s signed rank test
for paired samples. Linear relationships between variables
were determined by means of simple linear regression. Cor-
relation coefficients were determined by rank correlation
using Spearman’s test and 2 test. The overall survival of
patients with lung cancer was examined by the Kaplan-Meier
methods, and differences were examined by the Log-rank
test. All analysis was done using the Stat-View software
package (Abacus Concepts Inc. Berkeley, CA) and was
considered significant when the p value was less than 0.05.
RESULTS
NFE2L2 Gene Mutation Status in Japanese
Patients with Lung Cancer
We used cDNA from the lung cancer tissue to directly
sequence the NFE2L2 gene after PCR reaction, 13 of 263
patients had mutation in the NFE2L2 gene (Figure 1). Six
were known mutations (V32G, R34Q, E79K, and E79Q) and
seven were novel mutations (D29Y, R34P, R34G, D77G, and
E79D) (Table 1). The NFE2L2 mutations were clustered in
exon 2 and resulted in amino acid changes in either the DLG
or the ETGE motif of the regulatory Neh2 domain.15 Matched
adjacent normal lung tissues were available in 10; in all of
them, the sequence was wild type, suggesting that the muta-
tions were somatic. All 13 patients were male and 12 were
smokers. Four (30.8%) were stage I, four were stage II, and
five (38.5%) were stage III. In addition, NFE2L2 mutation
had a tendency to be more frequently found in advanced
stages (pStage II-IV versus I; p  0.0812). Seventy-eight
patients had EGFR mutation at the kinase domain. The
NFE2L2 mutation was exclusive with the EGFR mutation.
Thirty-four patients including one NFE2L2 mutant patient
received adjuvant or neoadjuvant chemotherapy.
The overall survival of 263 patients with lung cancer
with follow-up through December 31, 2009, was studied in
reference to the NFE2L2 mutation status. The patients with
NFE2L2 mutation (n  13, 8 were dead) had significantly
worse prognosis than the patients with wild type NFE2L2
(n  250, 72 were dead) (Log-rank test, p  0.0032,
Breslow-Gehan-Wilcoxon test; p  0.0028) (Figure 2). The
multivariate analyses revealed that pathologic stage (p 
0.0001, hazard ratio  2.989, 1.864–4.793) and NFE2L2
mutation (p  0.0379, hazard ratio  2.183, 1.045–4.566)
were the significant prognostic factors (Table 2). Within the
patients with squamous cell carcinoma, the patients with
NFE2L2 mutation (n  13, 8 were dead) had significantly
worse prognosis than the patients with wild type NFE2L2
FIGURE 1. Five novel NFE2L2 gene mutations. GAT  TAT
(D29Y, Asp  Tyr), CGG  CCA (R34P, Arg  Pro), CGA 
GGA (R34G, Arg  Gly), GAT  GGT (D77G, Asp  Gly),
and GAG  GAC (E79D, Glu  Asp).
TABLE 1. NFE2L2 Mutations
Sample
Nucleotide
Mutation
Amino Acid
Change Histology Gender Age
06–02 85 G-T D29Y (Asp  Tyr) SCC Male 58
98–14 95 T-G V32G (Val  Gly) SCC Male 74
98–48 100 C-G R34G (Arg  Gly) SCC Male 74
98–13 101 G-C R34P (Arg  Pro) SCC Male 63
01–18 101 G-A R34Q (Arg  Gln) SCC Male 65
02–39 101 G-A R34Q (Arg  Gln) SCC Male 66
03–40 101 G-A R34Q (Arg  Gln) SCC Male 79
01–25 230 A-G D77G (Asp  Gly) SCC Male 76
02–25 235 G-C E79Q (Glu  Gln) SCC Male 77
06–42 235 G-A E79K (Glu  Lys) SCC Male 77
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(n  111, 32 were dead) (Log-rank test, p  0.0127,
Breslow-Gehan-Wilcoxon test; p  0.0212). Within the male
patients with lung cancer, the patients with NFE2L2 mutation
(n  13, 8 were dead) had significantly worse prognosis than
the patients with wild type NFE2L2 (n  177, 57 were dead)
(Log-rank test, p  0.0193, Breslow-Gehan-Wilcoxon test;
p  0.018) (Figure 3).
DISCUSSION
We sequenced the NFE2L2 gene using the cDNA from
263 lung cancer tissue and found that NFE2L2 mutation was
correlated with male gender, smoking history, squamous
histology, and poor prognosis. This was in agreement with a
previous report and suggests a relationship between the
NFE2L2 mutation and tobacco smoke.10 The possible consti-
tutive activation of NFE2L2 by somatic mutation at E3 ligase
recognition sites of the Neh2 domain has been identified in
lung cancers and head and neck cancers.10
The preferential NEF2L2 mutations among patients
diagnosed with squamous cell carcinoma could also be ex-
plained by stress-related NFE2L2-dependent intervention to
squamous cell lineage differentiation. Malignant develop-
ment induced by NFE2L2-mediated gene expression profile
seems to be more complicated because a number of genes
involved in cell proliferation are transcriptionally modulated
by NFE2L2 through glutathione as the effectors.16 The asso-
ciation of NFE2L2 mutation and poor prognosis of lung
cancers suggested that a direct role of NFE2L2 mutation in
tumor progression. Constitutive expression of NFE2L2 could
provide a survival advantage to invasive and metastatic can-
cer cells, by adaptation to microenvironment on evolution of
chemoresistance in cancer cells under hypoxia.17,18 Both the
degree of CDDP-induced DNA crosslinking and the degree
of number of apoptosed cells were increased significantly in
A549 cells transfected with NFE2L2-siRNA.19 The expres-
sion of multidrug resistance-associated proteins, the drug
efflux proteins, was also significantly reduced in NFE2L2-
silenced A549 cells.19 A recent report showed that inhibition
of NFE2L2 function restored cisplatin (CDDP) sensitivity in
human ovarian cancer SKOV-3 cells.20
Cross-talk between tumor hypoxia and induction of
NFE2L2 has also been suggested.21 NFE2L2 knockdown by
NFE2L2-siRNA inhibited the proliferation of lung cancer
cells.19 The growth-inhibitory properties of NFE2L2 suppres-
sion are likely to be attributable to its induction of cell cycle
arrest at G1 phase in A549 and HCI-H292 cells.19 The cell
cycle arrest was associated with the repression of pRb phos-
phorylation in these cells.19 Hypoxia stimulates the NFE2L2
transcriptional response via EGFR kinase signaling.22 EGFR-
activated signaling and actin remodeling regulates cyclic-
stretch-induced NFE2L2 transcriptional response and subse-
quent antioxidant response element expression.23 In our
analysis, EGFR and NEF2L2 were found to be exclusive with
each other.
In vitro, wild type NFE2L2 was efficiently polyubiq-
uitinated while mutant NFE2L2 proteins were only weakly
polyubiquitinated after treatment with MG132.10 Wild-type
NFE2L2 protein decreased rapidly whereas mutant NFE2L2
proteins were degraded more slowly, having half-lives of
approximately twice that of wild type.10 In addition, mutant
FIGURE 2. The patient with NFE2L2 mutation in coding
region (n  13, 8 were dead; mean survival  54.7 months)
was significantly worse prognosis than the patient with wild
type NFE2L2 (n  250, 72 were dead; mean survival  73.4
months) (Log-rank test, p  0.0032, Breslow-Gehan-Wil-
coxon test, p  0.0028).
TABLE 2. Clinicopathological Data of 263 Patients with
Lung Cancer
Factors
NFE2L2 Gene Status
p
Wild-Type
Patients
Mutant
Patients
Mean age (yr)
64.9  9.0 250 13
Stage
I 146 (58.4%) 4 (30.8%) 0.0812
II-IV 104 (41.6%) 9 (69.2%)
Lymph node metastasis
N0 177 (70.8%) 6 (46.2%) 0.0697
N 73 (29.2%) 7 (53.8%)
Smoking
Never smoker 76 (30.4%) 1 (7.7%) 0.1165
Smoker 174 (69.6%) 12 (92.3%)
EGFR mutation
Wild type 142 (56.8%) 13 (100%) 0.1207
Mutation 78 (43.2%) 0 (0%)
Pathological subtypes
SCC 109 (43.6%) 13 (100%) 0.0001
Non-SCC 141 (56.4%) 0 (0%)
Age
65 112 (44.8%) 5 (38.5%) 0.7784
65 138 (55.2%) 8 (61.5%)
Gender
Male 177 (69.2%) 13 (100%) 0.0001
Female 73 (30.8%) 0 (0%)
N, lymph node metastasis positive; SCC, squamous cell carcinoma.
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NFE2L2 proteins were significantly more active than wild
type NFE2L2 by analyzing luciferase activity.
In summary, NFE2L2 mutation may play a role in the
progression of squamous cell carcinoma in male smokers.
Hence, inactivation of the NFE2L2 pathway may become
a therapeutic strategy to reinforce this treatment for this
malignancy.
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FIGURE 3. Kaplan-Meier curve of overall survival
within squamous cell carcinoma (left) and within
male (right) separated by NFE2L2 mutation.
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